// STATE LEGISLATION TRACKER

Missouri HB 544: Modifies provisions relating to abortion

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Missouri
Bill: HB 544
Filed: 2023-01-03
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Missouri HB 544 is an abortion bill, not a peptide-access bill. Based on the title, summary, and available bill text, it does not regulate compounded peptides, off-label prescribing, telehealth prescribing, NP/naturopath scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct impact on compounded peptide access
No change found for telehealth peptide prescribing
No change found for NP or naturopath peptide scope
No 503A/503B compounding language found
No controlled-substance or PDMP peptide issue found

What to Watch For

Note The bill is about abortion law changes, so peptide users do not need to track it for access or prescribing changes.

Note A passing reference to biological peptides in fetal-pain language does not affect therapeutic peptide use.

Note Clinicians should separate this from pharmacy, compounding, telehealth, or scope-of-practice bills.

Where the Bill Stands

The 2023 bill was referred to House Children and Families on May 12, 2023, and no passage was found before that session ended.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws